Síguenos en Twitter     Síguenos en Facebook     Síguenos en YouTube     Siguenos en Linkedin     Correo Grupsagessa     Gmail     Yahoo Mail     Dropbox     Instagram     Slack     Google Drive     Print     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon


Mi foto
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com


Buscar en contenido


sábado, 29 de septiembre de 2018

Clostridium Difficile Infection (2018 IDSA Guidelines)

PulmCCM - September 28, 2018 - By Kenny Jon-Emile

...In general I find the IDSA guidelines to be of excellent quality with fair and reasonable assessment of the evidence. I find their approach to diagnosis – which is inherently Bayesian – to be an admirable synthesis of the current literature. It seems prudent to set forth institutional guidelines for C. difficile testing bearing in mind the inherent imperfection of recipe-based medicine – especially in the immunocompromised. Equally important is to know the diagnostic characteristics of the bioassays employed in one’s hospital.

The previous guidelines also relied upon risk assessment to guide treatment of C. difficile. While the 2018 approach follows suit, treatment is now the same for mild and severe disease. This follows – since publication of the last guidelines – the observed superiority of vancomycin in all disease severities; accordingly, oral metronidazole should rarely be considered..."